Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRB | O95718 | 7/20 | 0.41 |
| ▸ | ESRRA | P11474 | 7/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 5/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | PDE9A | O76083 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3893950 | 0.90 | ESRRB (0.41) | ESRRBESRRAESR1ESR2GRIN1 | |
| SCHEMBL3903116 | 0.86 | ESRRB (0.40) | ESRRBESRRAESR1ESR2GRIN1 | |
| SCHEMBL3897120 | 0.83 | ESRRB (0.41) | ESRRBESRRAESR1ESR2DPP4 | |
| SCHEMBL3897670 | 0.82 | ESRRB (0.41) | ESRRBESRRAESR1ESR2DPP4 | |
| SCHEMBL3899817 | 0.82 | DPP4 (0.49) | DPP4ALDH1A1HPGDKDM4E | |
| SCHEMBL4708341 | 0.80 | DPP4 (0.38) | GRIN1GRIN2BDPP4 | |
| SCHEMBL4735167 | 0.79 | DPP4 (0.38) | ESRRBESRRAESR1ESR2GRIN1 | |
| SCHEMBL4708340 | 0.79 | GRIN1 (0.36) | ESRRBESRRAESR1ESR2GRIN1 | |
| SCHEMBL3903159 | 0.78 | DPP4 (0.41) | DPP4 | |
| SCHEMBL3906128 | 0.74 | DPP4 (0.43) | ESRRBESRRAESR1ESR2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547710-B2 | Fused heterocyclic compounds as peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-16 | — | — | US | disclosed |
| EP-1527049-B8 | FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2008-10-29 | — | — | EP | disclosed |
| EP-1527049-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1910362-A1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008021048-A2 | ADP-RIBOSYLTRANSFERASE BASED METHODS AND COMPOSITIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007019345-A1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20060135530-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1527049-A2 | FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004014860-A2 | FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135530-A1 | Fused heterocyclic compounds | NR4A3, DPP3, INSR | ESRRB 206/4885ESRRA 171/4885ESR1 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.